Skip to main content

Table 1 Distributions of potential risk factors for occurrence of cardiovascular events in RA patients at baseline

From: Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature

  N = 480
Demographics  
Sex (n,% female) 347 (72.3)
Age (mean, SD) 59.0 (13.0)
Traditional CV risk factors  
Smoking, current (n,%) 114 (23.8)
Systolic blood pressure (mmHg, mean, SD) 144.0 (22.9)
Total cholesterol (mmol/L, SD) 5.3 (0.99)
LDL cholesterol (mmol/L, SD) 3.1 (0.83)
Triglycerides (mmol/L, SD) 1.3 (0.65)
Atherogenic index (mean, SD) 3.7 (1.1)
GlyHb (%, mean, SD) 5.8 (0.67)
SCORE 10-year estimated CV risk (%, SD)) 5.7 (4.9)
Inflammatory markers  
ESR (mm/hr, mean, SD) 16.5 (14.9)
Hs CRP (mg/L, mean, SD) 7.0 (10.0)
RA disease characteristics  
RA disease duration (years; median, 25th-75th percentile) 4.2 (1.5-11.3)
Seropositive (anti-CCP and/or IgMRF; n,%) 286 (63.3)
Erosions (n,%) 198 (42.2)
DAS 28 (mean, SD) 2.5 (1.2)
Remission (n,%) 223 (72.1)
Medication  
DMARD (n,%) 350 (72.9)
MTX (n,%) 291 (60.6)
TNFα inhibitor (n,%) 105 (21.9)
NSAID (n,%) 177 (36.9)
Corticosteroids (n,%) 68 (14.2)
  1. (RA: rheumatoid arthritis; CV: cardiovascular; SD: standard deviation; LDL: low density lipoprotein; GlyHb: glycated hemoglobin; ESR: erythrocyte sedimentation rate; Hs CRP: high sensitivity C-reactive protein; anti CCP: anti cyclic citrullinated protein; IgM RF: IgM rheumatoid factor; DAS28: disease activity score in 28 joints; DMARD: disease modifying antirheumatic drug; MTX: methotrexate; TNF inhibitor: tumour necrosis factor α inhibitor; NSAID: non steroidal anti inflammatory drug).